Background:

TA-1801 is a hypolipidemic agent.

TA-1801 inhibits platelet aggregation in vitro[1].

TA-1801 reduces serum cholesterol and triglyceride levels by 23% and 35%, respectively, at a dose of 0.05% in a diet in normal rats, and it is about 10 times more active in hereditary hyperlipidemic rats (THLR/1) than in normal rats[1].

[1]. Moriya T, et al. Synthesis of ethyl 2-(4-chlorophenyl)-5-(2-furyl)-4-oxazoleacetate, a hypolipidemic agent, and related compounds. J Med Chem. 1988 Jun;31(6):1197-204.